Structure and function of SET and MYND domain-containing proteins

International Journal of Molecular Sciences

Volumn 16, Issue 1, 2015, Pages 1406-1428

  Spellmon, Nicholas ^a   Holcomb, Joshua ^a   Trescott, Laura ^a   Sirinupong, Nualpun ^b   Yang, Zhe ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

MYND (Myeloid Nervy DEAF1); SET (Suppressor of variegation, Enhancer of Zeste, Trithorax); SMYD (SET and MYND domain containing proteins); Structure and function

Indexed keywords

AZ 505; HISTONE LYSINE METHYLTRANSFERASE INHIBITOR; HISTONE METHYLTRANSFERASE; LEUCINE; MACROGOL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PHENYLALANINE; PROLINE; PROTEIN P53; S ADENOSYLHOMOCYSTEINE; SET AND MYND DOMAIN CONTAINING PROTEIN; SINEFUNGIN; SMYD1 PROTEIN; SMYD2 PROTEIN; SMYD3 PROTEIN; SMYD4 PROTEIN; SMYD5 PROTEIN; TYROSINE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; DNA BINDING PROTEIN; HISTONE; HISTONE LYSINE METHYLTRANSFERASE; TRANSCRIPTION FACTOR; ZINC FINGER PROTEIN;

BINDING SITE; CARBOXY TERMINAL SEQUENCE; DRUG DESIGN; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HYDROGEN BOND; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN METHYLATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; CHEMISTRY; CYTOLOGY; HUMAN; METABOLISM; PROTEIN TERTIARY STRUCTURE; SKELETAL MUSCLE;

BINDING SITES; DNA-BINDING PROTEINS; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; MUSCLE, SKELETAL; PROTEIN STRUCTURE, TERTIARY; SUBSTRATE SPECIFICITY; TRANSCRIPTION FACTORS; ZINC FINGERS;

EID: 84920885195     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16011406     Document Type: Review

References (73)

1. Gottlieb, P.D.; Pierce, S.A.; Sims, R.J.; Yamagishi, H.; Weihe, E.K.; Harriss, J.V.; Maika, S.D.; Kuziel, W.A.; King, H.L.; Olson, E.N, et al. Bop encodes a muscle-restricted protein containing MYND and SET domains and is essential for cardiac differentiation and morphogenesis. Nat. Genet. 2002, 31, 25–32.
2. Hamamoto, R.; Furukawa, Y.; Morita, M.; Iimura, Y.; Silva, F.P.; Li, M.; Yagyu, R.; Nakamura, Y. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat. Cell Biol. 2004, 6, 731–740.
3. Brown, M.A.; Sims, R.J., III; Gottlieb, P.D.; Tucker, P.W. Identification and characterization of Smyd2: A split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. Mol. Cancer 2006, 5, doi:10.1186/1476-4598-5-26.
4. Huang, J.; Perez-Burgos, L.; Placek, B.J.; Sengupta, R.; Richter, M.; Dorsey, J.A.; Kubicek, S.; Opravil, S.; Jenuwein, T.; Berger, S.L. Repression of p53 activity by smyd2-mediated methylation. Nature 2006, 444, 629–632.
5. Mazur, P.K.; Reynoird, N.; Khatri, P.; Jansen, P.W.; Wilkinson, A.W.; Liu, S.; Barbash, O.; van Aller, G.S.; Huddleston, M.; Dhanak, D, et al. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature 2014, 510, 283–287.
6. Du, S.J.; Tan, X.; Zhang, J. SMYD proteins: Key regulators in skeletal and cardiac muscle development and function. Anat. Rec. 2014, 297, 1650–1662.
7. Sirinupong, N.; Brunzelle, J.; Ye, J.; Pirzada, A.; Nico, L.; Yang, Z. Crystal structure of cardiac-specific histone methyltransferase smyd1 reveals unusual active site architecture. J. Biol. Chem. 2010, 285, 40635–40644.
8. Berger, S.L. The complex language of chromatin regulation during transcription. Nature 2007, 447, 407–412.
9. Liu, Y.; Chen, W.; Gaudet, J.; Cheney, M.D.; Roudaia, L.; Cierpicki, T.; Klet, R.C.; Hartman, K.; Laue, T.M.; Speck, N.A, et al. Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO’s activity. Cancer Cell 2007, 11, 483–497.
10. Spadaccini, R.; Perrin, H.; Bottomley, M.J.; Ansieau, S.; Sattler, M. Structure and functional analysis of the MYND domain. J. Mol. Biol. 2006, 358, 498–508.
11. Sirinupong, N.; Brunzelle, J.; Doko, E.; Yang, Z. Structural insights into the autoinhibition and posttranslational activation of histone methyltransferase SMYD3. J. Mol. Biol. 2011, 406, 149–159.
12. Jiang, Y.; Sirinupong, N.; Brunzelle, J.; Yang, Z. Crystal structures of histone and p53 methyltransferase SMYD2 reveal a conformational flexibility of the autoinhibitory C-terminal domain. PLoS One 2011, 6, e21640.
13. Allan, R.K.; Ratajczak, T. Versatile TPR domains accommodate different modes of target protein recognition and function. Cell Stress Chaperones 2011, 16, 353–367.
14. Abu-Farha, M.; Lambert, J.P.; Al-Madhoun, A.S.; Elisma, F.; Skerjanc, I.S.; Figeys, D. The tale of two domains: Proteomics and genomics analysis of SMYD2, a new histone methyltransferase. Mol. Cell. Proteomics 2008, 7, 560–572.
15. Tan, X.; Rotllant, J.; Li, H.; de Deyne, P.; Du, S.J. SmyD1, a histone methyltransferase, is required for myofibril organization and muscle contraction in zebrafish embryos. Proc. Natl. Acad. Sci. USA 2006, 103, 2713–2718.
16. Medjkane, S.; Cock-Rada, A.; Weitzman, J.B. Role of the SMYD3 histone methyltransferase in tumorigenesis: Local or global effects? Cell Cycle 2012, 11, doi:10.4161/cc.20415.
17. Cock-Rada, A.M.; Medjkane, S.; Janski, N.; Yousfi, N.; Perichon, M.; Chaussepied, M.; Chluba, J.; Langsley, G.; Weitzman, J.B. SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9. Cancer Res. 2012, 72, 810–820.
18. Lin, Y.M.; Furukawa, Y.; Tsunoda, T.; Yue, C.T.; Yang, K.C.; Nakamura, Y. Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. Oncogene 2002, 21, 4120–4128.
19. Okabe, H.; Satoh, S.; Kato, T.; Kitahara, O.; Yanagawa, R.; Yamaoka, Y.; Tsunoda, T.; Furukawa, Y.; Nakamura, Y. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cdna microarray: Identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res. 2001, 61, 2129–2137.
20. Hu, L.; Zhu, Y.T.; Qi, C.; Zhu, Y.J. Identification of SMYD4 as a potential tumor suppressor gene involved in breast cancer development. Cancer Res. 2009, 69, 4067–4072.
21. Thompson, E.C.; Travers, A.A. A drosophila SMYD4 homologue is a muscle-specific transcriptional modulator involved in development. PLoS One 2008, 3, e3008.
22. Stender, J.D.; Pascual, G.; Liu, W.; Kaikkonen, M.U.; Do, K.; Spann, N.J.; Boutros, M.; Perrimon, N.; Rosenfeld, M.G.; Glass, C.K. Control of proinflammatory gene programs by regulated trimethylation and demethylation of histone h4k20. Mol. Cell 2012, 48, 28–38.
23. Saddic, L.A.; West, L.E.; Aslanian, A.; Yates, J.R., III Rubin, S.M.; Gozani, O.; Sage, J. Methylation of the retinoblastoma tumor suppressor by SMYD2. J. Biol. Chem. 2010, 285, 37733–37740.
24. Cho, H.S.; Hayami, S.; Toyokawa, G.; Maejima, K.; Yamane, Y.; Suzuki, T.; Dohmae, N.; Kogure, M.; Kang, D.; Neal, D.E, et al. RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. Neoplasia 2012, 14, 476–486.
25. Komatsu, S.; Imoto, I.; Tsuda, H.; Kozaki, K.I.; Muramatsu, T.; Shimada, Y.; Aiko, S.; Yoshizumi, Y.; Ichikawa, D.; Otsuji, E, et al. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis 2009, 30, 1139–1146.
26. Sajjad, A.; Novoyatleva, T.; Vergarajauregui, S.; Troidl, C.; Schermuly, R.T.; Tucker, H.O.; Engel, F.B. Lysine methyltransferase SMYD2 suppresses p53-dependent cardiomyocyte apoptosis. Biochim. Biophys. Acta 2014, 1843, 2556–2562.
27. Piao, L.; Kang, D.; Suzuki, T.; Masuda, A.; Dohmae, N.; Nakamura, Y.; Hamamoto, R. The histone methyltransferase SMYD2 methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in cancer cells. Neoplasia 2014, 16, 257–264.
28. Kunizaki, M.; Hamamoto, R.; Silva, F.P.; Yamaguchi, K.; Nagayasu, T.; Shibuya, M.; Nakamura, Y.; Furukawa, Y. The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3. Cancer Res. 2007, 67, 10759–10765.
29. Ferguson, A.D.; Larsen, N.A.; Howard, T.; Pollard, H.; Green, I.; Grande, C.; Cheung, T.; Garcia-Arenas, R.; Cowen, S.; Wu, J, et al. Structural basis of substrate methylation and inhibition of SMYD2. Structure 2011, 19, 1262–1273.
30. Foreman, K.W.; Brown, M.; Park, F.; Emtage, S.; Harriss, J.; Das, C.; Zhu, L.; Crew, A.; Arnold, L.; Shaaban, S, et al. Structural and functional profiling of the human histone methyltransferase SMYD3. PLoS One 2011, 6, e22290.
31. Xu, S.; Zhong, C.; Zhang, T.; Ding, J. Structure of human lysine methyltransferase smyd2 reveals insights into the substrate divergence in smyd proteins. J. Mol. Cell Biol. 2011, 3, 293–300.
32. Jiang, Y.; Trescott, L.; Holcomb, J.; Zhang, X.; Brunzelle, J.; Sirinupong, N.; Shi, X.; Yang, Z. Structural insights into estrogen receptor alpha methylation by histone methyltransferase SMYD2, a cellular event implicated in estrogen signaling regulation. J. Mol. Biol. 2014, 426, 3413–3425.
33. Wang, L.; Li, L.; Zhang, H.; Luo, X.; Dai, J.; Zhou, S.; Gu, J.; Zhu, J.; Atadja, P.; Lu, C, et al. Structure of human SMYD2 protein reveals the basis of p53 tumor suppressor methylation. J. Biol. Chem. 2011, 286, 38725–38737.
34. Sims, R.J., III; Weihe, E.K.; Zhu, L.; O’Malley, S.; Harriss, J.V.; Gottlieb, P.D. M-bop, a repressor protein essential for cardiogenesis, interacts with sknac, a heartand muscle-specific transcription factor. J. Biol. Chem. 2002, 277, 26524–26529.
35. Couture, J.F.; Collazo, E.; Brunzelle, J.S.; Trievel, R.C. Structural and functional analysis of set8, a histone h4 lys-20 methyltransferase. Genes Dev. 2005, 19, 1455–1465.
36. Wilson, J.R.; Jing, C.; Walker, P.A.; Martin, S.R.; Howell, S.A.; Blackburn, G.M.; Gamblin, S.J.; Xiao, B. Crystal structure and functional analysis of the histone methyltransferase SET7/9. Cell 2002, 111, 105–115.
37. Wu, J.; Cheung, T.; Grande, C.; Ferguson, A.D.; Zhu, X.; Theriault, K.; Code, E.; Birr, C.; Keen, N.; Chen, H. Biochemical characterization of human SET and MYND domain-containing protein 2 methyltransferase. Biochemistry 2011, 50, 6488–6497.
38. Kateb, F.; Perrin, H.; Tripsianes, K.; Zou, P.; Spadaccini, R.; Bottomley, M.; Franzmann, T.M.; Buchner, J.; Ansieau, S.; Sattler, M. Structural and functional analysis of the DEAF-1 and BS69 MYND domains. PLoS One 2013, 8, e54715.
39. Abu-Farha, M.; Lanouette, S.; Elisma, F.; Tremblay, V.; Butson, J.; Figeys, D.; Couture, J.F. Proteomic analyses of the SMYD family interactomes identify HSP90 as a novel target for SMYD2. J. Mol. Cell Biol. 2011, 3, 301–308.
40. Xu, S.; Wu, J.; Sun, B.; Zhong, C.; Ding, J. Structural and biochemical studies of human lysine methyltransferase Smyd3 reveal the important functional roles of its post-SET and TPR domains and the regulation of its activity by DNA binding. Nucleic Acids Res. 2011, 39, 4438–4449.
41. Luo, X.G.; Zhang, C.L.; Zhao, W.W.; Liu, Z.P.; Liu, L.; Mu, A.; Guo, S.; Wang, N.; Zhou, H.; Zhang, T.C. Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells. Cancer Lett. 2014, 344, 129–137.
42. Liu, C.; Xu, D.; Han, H.; Fan, Y.; Schain, F.; Xu, Z.; Claesson, H.E.; Bjorkholm, M.; Sjoberg, J. Transcriptional regulation of 15-lipoxygenase expression by histone h3 lysine 4 methylation/demethylation. PLoS One 2012, 7, e52703.
43. Kim, H.; Heo, K.; Kim, J.H.; Kim, K.; Choi, J.; An, W. Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription. J. Biol. Chem. 2009, 284, 19867–19877.
44. Van Aller, G.S.; Reynoird, N.; Barbash, O.; Huddleston, M.; Liu, S.; Zmoos, A.F.; McDevitt, P.; Sinnamon, R.; Le, B.; Mas, G, et al. Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. Epigenetics 2012, 7, 340–343.
45. Zhang, X.; Yang, Z.; Khan, S.I.; Horton, J.R.; Tamaru, H.; Selker, E.U.; Cheng, X. Structural basis for the product specificity of histone lysine methyltransferases. Mol. Cell 2003, 12, 177–185.
46. Xiao, B.; Jing, C.; Wilson, J.R.; Walker, P.A.; Vasisht, N.; Kelly, G.; Howell, S.; Taylor, I.A.; Blackburn, G.M.; Gamblin, S.J. Structure and catalytic mechanism of the human histone methyltransferase SET7/9. Nature 2003, 421, 652–656.
47. Zhang, X.; Tanaka, K.; Yan, J.; Li, J.; Peng, D.; Jiang, Y.; Yang, Z.; Barton, M.C.; Wen, H.; Shi, X. Regulation of estrogen receptor alpha by histone methyltransferase smyd2-mediated protein methylation. Proc. Natl. Acad. Sci. USA 2013, 110, 17284–17289.
48. Onuoha, S.C.; Coulstock, E.T.; Grossmann, J.G.; Jackson, S.E. Structural studies on the co-chaperone Hop and its complexes with Hsp90. J. Mol. Biol. 2008, 379, 732–744.
49. Song, Y.; Masison, D.C. Independent regulation of Hsp70 and Hsp90 chaperones by Hsp70/Hsp90-organizing protein sti1 (Hop1). J. Biol. Chem. 2005, 280, 34178–34185.
50. Wu, B.; Li, P.; Liu, Y.; Lou, Z.; Ding, Y.; Shu, C.; Ye, S.; Bartlam, M.; Shen, B.; Rao, Z. 3D structure of human FK506-binding protein 52: Implications for the assembly of the glucocorticoid receptor/Hsp90/immunophilin heterocomplex. Proc. Natl. Acad. Sci. USA 2004, 101, 8348–8353.
51. Davies, T.H.; Sanchez, E.R. FKBP52. Int. J. Biochem. Cell Bsiol. 2005, 37, 42–47.
52. Deshpande, C.N.; Harrop, S.J.; Boucher, Y.; Hassan, K.A.; Di Leo, R.; Xu, X.; Cui, H.; Savchenko, A.; Chang, C.; Labbate, M, et al. Crystal structure of an integron gene cassette-associated protein from vibrio cholerae identfies a cationic drug-binding module. PLoS One 2011, 6, e16934.
53. Van den Hemel, D.; Brige, A.; Savvides, S.N.; van Beeumen, J. Ligand-induced conformational changes in the capping subdomain of a bacterial old yellow enzyme homologue and conserved sequence fingerprints provide new insights into substrate binding. J. Biol. Chem. 2006, 281, 28152–28161.
54. Aufhammer, S.W.; Warkentin, E.; Ermler, U.; Hagemeier, C.H.; Thauer, R.K.; Shima, S. Crystal structure of methylenetetrahydromethanopterin reductase (Mer) in complex with coenzyme F420: Architecture of the F420/FMN binding site of enzymes within the nonprolyl cis-peptide containing bacterial luciferase family. Protein Sci. 2005, 14, 1840–1849.
55. Sakamoto, L.H.; Andrade, R.V.; Felipe, M.S.; Motoyama, A.B.; Pittella Silva, F. Smyd2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor. Leuk. Res. 2014, 38, 496–502.
56. Borlak, J.; Thum, T. Hallmarks of ion channel gene expression in end-stage heart failure. FASEB J. 2003, 17, 1592–1608.
57. Gambetta, K.; Al-Ahdab, M.K.; Ilbawi, M.N.; Hassaniya, N.; Gupta, M. Transcription repression and blocks in cell cycle progression in hypoplastic left heart syndrome. Am. J. Physiol. Heart Circ. Physiol. 2008, 294, H2268–H2275.
58. Komatsu, S.; Ichikawa, D.; Hirajima, S.; Nagata, H.; Nishimura, Y.; Kawaguchi, T.; Miyamae, M.; Okajima, W.; Ohashi, T.; Konishi, H, et al. Overexpression of Smyd2 contributes to malignant outcome in gastric cancer. Br. J. Cancer 2014, 16, doi:10.1038/bjc.2014.543.
59. Liu, C.; Wang, C.; Wang, K.; Liu, L.; Shen, Q.; Yan, K.; Sun, X.; Chen, J.; Liu, J.; Ren, H, et al. Smyd3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription. J. Natl. Cancer Inst. 2013, 105, 1719–1728.
60. Wang, S.Z.; Luo, X.G.; Shen, J.; Zou, J.N.; Lu, Y.H.; Xi, T. Knockdown of Smyd3 by RNA interference inhibits cervical carcinoma cell growth and invasionin vitro. BMB Rep. 2008, 41, 294–299.
61. Hamamoto, R.; Silva, F.P.; Tsuge, M.; Nishidate, T.; Katagiri, T.; Nakamura, Y.; Furukawa, Y. Enhanced Smyd3 expression is essential for the growth of breast cancer cells. Cancer Sci. 2006, 97, 113–118.
62. O’Byrne, K.J.; Baird, A.M.; Kilmartin, L.; Leonard, J.; Sacevich, C.; Gray, S.G. Epigenetic regulation of glucose transporters in non-small cell lung cancer. Cancers 2011, 3, 1550–1565.
63. Vieira, F.Q.; Costa-Pinheiro, P.; Ramalho-Carvalho, J.; Pereira, A.; Menezes, F.D.; Antunes, L.; Carneiro, I.; Oliveira, J.; Henrique, R.; Jeronimo, C. Deregulated expression of selected histone methylases and demethylases in prostate carcinoma. Endocr. Relat. Cancer 2014, 21, 51–61.
64. He, C.; Xu, J.; Zhang, J.; Xie, D.; Ye, H.; Xiao, Z.; Cai, M.; Xu, K.; Zeng, Y.; Li, H, et al. High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma. Hum. Pathol. 2012, 43, 1425–1435.
65. Luo, X.G.; Xi, T.; Guo, S.; Liu, Z.P.; Wang, N.; Jiang, Y.; Zhang, T.C. Effects of Smyd3 overexpression on transformation, serum dependence, and apoptosis sensitivity in NIH3T3 cells. IUBMB Life 2009, 61, 679–684.
66. Luo, X.G.; Zou, J.N.; Wang, S.Z.; Zhang, T.C.; Xi, T. Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells. IUBMB Life 2010, 62, 194–199.
67. Sponziello, M.; Durante, C.; Boichard, A.; Dima, M.; Puppin, C.; Verrienti, A.; Tamburrano, G.; di Rocco, G.; Redler, A.; Lacroix, L, et al. Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours. Mol. Cell. Endocrinol. 2014, 392, 8–13.
68. Dong, S.W.; Zhang, H.; Wang, B.L.; Sun, P.; Wang, Y.G.; Zhang, P. Effect of the downregulation of SMYD3 expression by RNAi on RIZ1 expression and proliferation of esophageal squamous cell carcinoma. Oncol. Rep. 2014, 32, 1064–1072.
69. Josse, R.; Dumont, J.; Fautrel, A.; Robin, M.A.; Guillouzo, A. Identification of early target genes of aflatoxin B1 in human hepatocytes, inter-individual variability and comparison with other genotoxic compounds. Toxicol. Appl. Pharmacol. 2012, 258, 176–187.
70. Gutmann, D.H.; Donahoe, J.; Perry, A.; Lemke, N.; Gorse, K.; Kittiniyom, K.; Rempel, S.A.; Gutierrez, J.A.; Newsham, I.F. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum. Mol. Genet. 2000, 9, 1495–1500.
71. Tran, Y.K.; Bogler, O.; Gorse, K.M.; Wieland, I.; Green, M.R.; Newsham, I.F. A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer. Cancer Res. 1999, 59, 35–43.
72. Wiesner, S.; Wybenga-Groot, L.E.; Warner, N.; Lin, H.; Pawson, T.; Forman-Kay, J.D.; Sicheri, F. A change in conformational dynamics underlies the activation of eph receptor tyrosine kinases. EMBO J. 2006, 25, 4686–4696.
73. Gosu, V.; Choi, S. Structural dynamic analysis of apo and ATP-bound IRAK4 kinase. Sci. Rep. 2014, 4, doi:10.1038/srep05748